Key result
Newer techniques like speckle-tracking imaging, cardiac magnetic resonance, and circulating biomarkers offer greater sensitivity for early detection of chemotherapy-induced cardiotoxicity than LVEF.
Answers are grounded in this paper and cite their sources.
Advanced diagnostic tools such as speckle-tracking imaging, cardiac magnetic resonance, and biomarkers offer improved sensitivity for detecting early chemotherapy-induced cardiotoxicity compared to traditional LVEF evaluation.
Cardiotoxicity is a rising issue connected to use of chemotherapy and radiotherapy in the treatment of neoplastic diseases. Early diagnosis during follow-up is of paramount importance, and careful surveillance is recommended. Evaluation of left ventricular ejection fraction by echocardiography and nuclear medicine techniques is widely used in clinical practice; however, their sensitivity in detecting early cardiac damage is low. New instruments like speckle-tracking imaging, cardiac magnetic resonance and cardiac circulating biomarkers are available to clinicians to best evaluate the onset and progression of cardiotoxic effects, improving the therapeutic management and final outcome for the patient.
No takes yet. Share an insight, caveat, or question.
Pizzino et al. (2014) conducted a review in Chemotherapy-induced cardiotoxicity. Advanced imaging and biomarkers (Speckle-tracking, CMR, troponin) vs. Conventional LVEF monitoring was evaluated. Newer techniques like speckle-tracking imaging, cardiac magnetic resonance, and circulating biomarkers offer greater sensitivity for early detection of chemotherapy-induced cardiotoxicity than LVEF.
Synapse has enriched 10 related papers. Consider them for comparative context: